{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '7.1.3.3 Non-Clinical Pharmacokinetics', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 56 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '7.1.3.4 Clinical Experience', '7.1.3.4.1 Introduction', 'Teprotumumab was originally developed by F. Hoffman-La Roche Ltd. for the treatment of', 'subjects with advanced solid tumors, including sarcoma. Development for this indication was', 'discontinued based on insufficient clinical efficacy and was not based on any observed safety', 'issues in the more than 700 subjects treated in the oncology program.', 'Teprotumumab is currently being developed by Horizon for subjects with moderate-to-severe', \"active TED (also known as Graves' Ophthalmopathy or Orbitopathy [GO] and Thyroid-\", 'Associated Ophthalmopathy [TAO]).', 'The pharmacokinetics (PK) of teprotumumab were characterized by Roche. A biomarker to', 'assess target interaction - increases in serum IGF-1 - was also identified. PK/PD modeling', 'indicated that concentrations of 20 g/mL resulted in > 90% IGF-1R receptor occupancy, and', 'that doses that produced teprotumumab trough blood concentrations of 20 g/mL were well', 'tolerated.', 'The clinical safety database of teprotumumab in oncology was likely confounded by the', 'comorbidity of late stage cancer and concomitant administration of other treatments. The', 'oncology studies, however, did identify a number of potential AEs of special interest (AESIs:', 'infusion-associated events, thrombocytopenia, hyperglycemia, and anemia) and these events', 'were monitored carefully in the initial study in TED subjects, TED01RV.', 'TED01RV was the first study in which non-oncology subjects received teprotumumab. This', 'study enrolled 87 subjects (43 teprotumumab; 44 placebo) between the ages of 18 and 75 years', 'with recent onset (9 months from diagnosis) moderate-to-severe active TED. The primary', 'efficacy endpoint was the overall responder rate (decreases from Baseline of > 2 points in overall', 'Clinical Activity Score [CAS] and > 2 mm in proptosis, provided that there was no deterioration', '[i.e., increases of > 2 points in CAS or > 2 mm in proptosis] in the non-study eye) at the end of', 'the 24-week treatment phase. In this study, the responder rate was significantly greater with', 'teprotumumab treatment compared to placebo (69% versus 20%; p < 0.001) at Week 24.', 'Therapeutic effects were rapid, with increased responder rates in the teprotumumab group', 'relative to placebo detected at Weeks 6, 12, and 18 (all p < 0.001). The secondary endpoints', '(QoL, proptosis, and CAS as continuous variables) all supported the primary analysis conclusion', 'that teprotumumab was superior to placebo in the treatment of TED. Population PK modeling in', 'TED01RV confirmed that trough concentrations were consistently above the 20 g/mL', 'threshold, which had been previously determined by Roche PK/PD modeling as resulting in', '> 90% IGF-1R occupancy in the tissues. Results of the TED01RV study were published in the', 'New England Journal of Medicine [Smith et al, 2017].', 'Of the AESIs identified in the oncology studies (i.e., infusion-associated events,', 'thrombocytopenia, hyperglycemia, and anemia), the only one that emerged in the initial trial in', 'subjects with TED was hyperglycemia. Among subjects treated with teprotumumab,', 'hyperglycemia was uniformly mild in non-diabetic subjects and adequately controlled by', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 57 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'adjusting standard anti-diabetic therapy in diabetic subjects. Importantly, hyperglycemia in all', 'teprotumumab-treated subjects was at Baseline levels after the end of the Treatment Period.', '7.1.3.4.2 Efficacy', 'The TED01RV study demonstrated that subjects with active moderate-to-severe TED', 'experienced statistically significant and clinically meaningful results in the proportion of', 'responders at Week 24 in the teprotumumab group relative to placebo (69% [29/42 subjects]', 'versus 20% [9/43 subjects], respectively; p < 0.001). Therapeutic effects were rapid, with', 'responder rates in the teprotumumab group significantly greater than those in the placebo group', 'at Weeks 6, 12, and 18 (all < 0.001). Specifically, the proptosis component of the responder', 'analysis showed a mean (standard error) reduction of 2.46 mm (0.20) in the teprotumumab group', 'compared to 0.15 mm (0.19) in the placebo group at Week 24 (p < 0.001).', 'The secondary endpoints (QoL, proptosis, and CAS as continuous variables) supported the', 'primary analysis conclusion that teprotumumab was superior to placebo in the treatment of this', 'population.', 'In conclusion, for subjects with active ophthalmopathy, teprotumumab was more effective than', 'placebo in reducing proptosis and the CAS.', '7.1.3.4.3 Pharmacokinetics', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 58 of 118']\n\n###\n\n", "completion": "END"}